A record of what Marketsmith India Analysis said publicly, with the source. Not advice.
“Bullish on GlaxoSmithKline Pharmaceuticals Ltd, recommending a buy at ₹3,156 with a target price of ₹3,560 in two to three months and a stop loss at ₹2,990. The recommendation is based on the company's focus on innovation, strong financial position, operational excellence, and supply chain strength.”
Marketsmith India Analysis’s track record (trackable calls only): 322 graded calls · 95% CI 22–32%
How this call is judged
A call is judged on closing prices only: a close at its target is a hit and a close at its stop is a miss. A call that states an entry starts at the first close that reaches it; if none does in the days allowed, it was never triggered, is not graded and counts toward no hit rate.
Entry: ₹3,156, as stated.
Target ₹3,560, stop ₹2,990, as stated.
Window: 90 days, the time frame the call states ("two to three months").
The stop ₹2,990 was reached on a close before the target ₹3,560. Miss.
The grader’s working: R3 TRADE_SETUP: entered ₹3156 on 2025-07-28 (stated entry ₹3156, LEVEL_CMP entry, filled); stop ₹2990 breached at close ₹2936.5 on 2025-08-01. Window 90 days — rule H1: the quote states "two to three months".
How it played out
How this is worked out- Target or stop first
- The stop was reached on a close before the target was.
- Time to target
- The target was not reached on a close inside the window.
- Worst close against it
- The closing price went as far as 6.96% against the call up to 1 Aug 2025, when the call was decided, measured from the entry price. Closing prices only; an intraday dip is never counted.
From the entry the grade used, on closing prices. This is a record of one past call and is not advice.